Adenoviral shuttle vectors to express short hairpin RNAs (shRNA) using RNA polymerase III (RNA pol III) promoters (mouse U6, human H1, or human U6) have been constructed in several laboratories including Welgen (Worcester, MA, USA), BD Biosciences (San Jose, CA, USA), Invitrogen (Carlsbad, CA, USA), and GeneScript (Piscataway, NJ, USA). Welgen and Invitrogen developed adenovirus shuttle vectors to express shRNA under the control of the human U6 or H1 promoter. BD Biosciences developed a shuttle vector to express shRNA under the control of the human U6 promoter with red fluorescent protein (RFP) expression to track transfection efficiency. GenScript and Zhao et al. (1) also developed a shuttle vector under the control of the human H1 promoter with a green fluorescent protein (GFP) marker. The activities of RNA pol III-driven promoters vary with cell type (2) . Therefore, the activities of these three different promoters should be tested to select the most efficient shRNA system. However, the cloning sites within these vectors among the different companies are different, and therefore, the shRNA oligonucleotide duplexes are not interchangeable.
We constructed three new adenoviral vectors based on the shuttle plasmid pShuttle (Stratagene, La Jolla, CA, USA). The vectors (pAd shRNA/mU6, pAd shRNA/H1, and pAd shRNA/ U6) all contain an shRNA expression cassette and an enhanced GFP (EGFP) marker, and all three constructs have the same cloning sites (Figure 1 ). The shRNA cassette is controlled under the mouse U6, the human H1, or the human U6 RNA pol III promoter. In our constructs, a 378-bp placeholder fragment was inserted between the cloning sites (BamHI and HindIII) used for insertion of the shRNA. This produces a double digested product that is significantly different in size from the single digested product, making it easy to distinguish during gel elution. Another difficulty with cloning an annealed shRNA duplex into a vector is screening inserted positive clones. In our vectors, a pair of screening primers (P1 and P1r) is located upstream of the H1 or U6 promoters and at the cytomegalovirus (CMV) promoter for 
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colony-direct PCR. The products can be distinguished by size: either 424 bp for pAd shRNA/H1 with a shRNA duplex insert or 355 bp without it. The primers can also be used for direct sequencing of the PCR products. These vectors also contain the EGFP cassette controlled under the CMV promoter, which allows monitoring of transfection or transduction at the single cell level.
We used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) silencing in mouse jejunal cells as a model to test the efficiency of these vectors. The GAPDH shRNA control insert obtained from Ambion (Austin, TX, USA) is annealed to doublestranded oligonucleotides with BamHI and HindIII sticky ends surrounding the shRNA template that targets the GAPDH messenger RNA (mRNA) (see the supplementary materials at BioTechniques' web site at www. BioTechniques.com for online posting). This annealed insert was ligated into the three vectors. A negative control nontargeting shRNA was also inserted into the hU6 vector. Adenoviruses were produced from these constructs using the AdEasy™ Adenoviral Vector System (Stratagene), according to the manufacturer's instructions (www.stratagene. com/manuals/240009. pdf). The titer was 1-5 × 10 11 plaque-forming unit (pfu)/mL. The adenoviruses were used to transduce primary cultures of mouse jejunal tunica muscularis cells. The cells were transduced with adenoviruses expressing either negative control shRNA or GAPDH shRNA. Two days after transduction, fibroblast cells and smooth muscle cells were all GFP positive, but network-forming cells showed about 10%-20% of cells GFP positive (data not shown). Some cell types such as skeletal muscle cells, endothelial cells, hematopoietic cells, and many tumor cells are known to be resistant to adenovirus infection due to a lack of the coxsackievirus and adenovirus receptor (CAR) (3). Several researchers have shown adenovirus transduction improved with the aid of cationic lipids, polymers, liposomes, EGTA, sodium caprate, or calcium phosphate (4-10). However, these reagents are toxic to primary cells and kill most of them after transduction. To improve transduction, we used an advanced nonliposomal transfection reagent, FuGENE™ 6 (Roche Applied Science, Indianapolis, IN, USA), in the amount of 3 μL FuGENE 6 plus 10 9 pfu viruses in a 6-well plate. This method showed minimal toxicity along with a high efficiency of transduction. Using this method, more than 90% of network-forming cells, as well as other cell types transduced with the negative control adenovirus and FuGENE 6, were GFP positive (Figure 2) . The same results were observed with cells transduced with the GAPDH shRNAexpressing adenovirus.
The cells transduced with the GAPDH shRNA-expressing adenovirus were harvested 2 days after transduction for protein analysis. GAPDH protein with a molecular mass of 37 kDa was detected by Western blot analysis. A representative blot is shown in Figure 3 . The reduction levels of protein were 80% (±6%), 88% (±4%) and 75% (±8%) in the cells transduced with GAPDH shRNA/mU6, GAPDH shRNA/H1, and GAPDH shRNA/ hU6, respectively, when compared to levels in the negative control shRNAtransduced cells (n = 2). Thus, the H1 promoter was slightly more effective than either the mU6 or hU6 promoter for the mouse jejunal cells. β-Actin protein with a molecular mass of 45 kDa was used as an endogenous control. The levels of this protein did not change following treatment with adenovirus. The promoter activity of these three adenoviruses was also tested in NIH3T3 cells. As expected, the mU6 promoter was more efficient than the H1 or the hU6 promoter. Reductions in the GAPDH mRNA were 76% (±3%) with mU6, 65% (±4%) with H1, and 52% (±6%) with hU6, respectively (n = 3).
In summary, we have constructed three new adenoviral shuttle vectors, pAd shRNA/mU6, pAd shRNA/H1, and pAd shRNA/hU6. This set of vectors has several advantages over other shRNA vectors. First, each vector contains an shRNA cassette that is under the control of a different promoter (mouse U6, the human H1, or U6 promoter), allowing users to select the most efficient shRNA system. Since all three constructs contain the same sites for cloning of the shRNA, the shRNA duplexes are easily interchangeable in all three vectors. Second, the use of screening primers allows us to pick up positive clones by a fast and accurate PCR-based technique. Third, the use of EGFP in the vector allows us to track the efficiency of transfection/ transduction in mammalian cells.
